Hematology

Filter

Highlights on Pierre Fabre EHA 2024 Symposium: Changing the face of EBV+ PTLD with allogeneic T-cell therapies

September 2024

Watch here the key takeaways from this year’s European Hematology Association (EHA) symposium that focused on the Management…

Clinical significance of progenitor cells in multiple myeloma

Prof Kenneth Anderson (Harvard Medical School, Boston, MA) chairs a discussion with Prof Leif Bergsagel (Mayo Clinic, Scottsdale, AZ) and Prof Gareth…

Prof John Gribben and Prof Andre Goy at ASH 2014: Treating mantle cell lymphoma (Part 3)

Prof John Gribben (Barts Cancer Institute, London, UK) interviews Prof Andre Goy (John Theurer Cancer Center, Hackensack, NJ) at the 2014 American Society…

ASH 2014: Recent investigational advances in mantle cell lymphoma treatment

Prof Simon Rule (Derriford Hospital, Plymouth, UK) at the 2014 American Society of Hematology (ASH) Annual Meeting discusses recent advances in the…

EMJ

ASH 2014: Phase II study of lenalidomide plus rituximab for mantle cell lymphoma (Part 2)

Dr Jia Ruan (Weill Cornell Medical College, New York, NY) at the 2014 American Society of Hematology (ASH) Annual Meeting discusses the clinical relevance…

EMJ

Prof John Gribben and Prof Marek Trněný at ASH 2014: Mantle cell lymphoma advances (Part 1)

At the 2014 American Society of Hematology (ASH) Annual Meeting, Prof John Gribben (Barts Cancer Institute, London, UK) and Prof Marek Trněný (Charles…

EMJ

ASH 2014: New therapies for mantle cell lymphoma

Prof Umberto Vitolo (Città della Salute e della Scienza di Torino, Turin, Italy) at the 2014 American Society of Hematology (ASH) Annual Meeting…

Loading posts...

« Previous 1 … 4 5 6